fbpx
 List – 54 Drug Patents that are Expiring in 2024

List – 54 Drug Patents that are Expiring in 2024

1

Mulpleta
Lusutrombopag

Sales:
200 Million Yen (2018)

PatentsExpiration Date
US7601746September 05, 2024
US8889722July 29, 2028
US8530668January 21, 2030

Dosage: Oral
Company: Shionogi Inc.
Ingredients: LUSUTROMBOPAG
Treatment: Thrombocytopenia

Invokamet XR
Canagliflozin; Metformin Hydrochloride

Sales:
$1.41 Billion (2016)

PatentsExpiration Date
US8785403July 30, 2024
US8222219March 11, 2025

Dosage: Tablet, Extended Release; Oral
Company: Janssen Pharmaceuticals Inc
Ingredients: Canagliflozin; Metformin Hydrochloride
Treatment: Type 2 Diabetes Mellitus

Revlimid
Lenalidomide

Sales:
$10.82 Billion (2019)

PatentsExpiration Date
US7855217November 24, 2024
US7465800April 27, 2027

Dosage: Oral
Company: Celgene Corp
Ingredients: LENALIDOMIDE
Treatment: Multiple Myeloma and Myelodysplastic Syndromes

Rydapt
Midostaurin

Sales:
$150 Million (2018)

PatentsExpiration Date
US7973031October 17, 2024
US8222244October 29, 2022

Dosage: Capsule; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Midostaurin
Treatment: Acute Myeloid Leukemia

Prevymis
Letermovir

Sales:
$370 Million (2020)

PatentsExpiration Date
US7196086May 22, 2024
US8513255May 22, 2024

Dosage: Solution; Intravenous
Company: Merck Sharp And Dohme Corp
Ingredients: Letermovir
Treatment: Cytomegalovirus (CMV) infection

Vyndaqela
Tafamidis Meglumine

Sales:
$259 Million (Jan-Sep 2019)

PatentsExpiration Date
US7214695April 27, 2024
US7214696December 19, 2023
US8168663December 19, 2023
US8653119January 28, 2024

Dosage: Capsule; Oral
Company: Foldrx Pharmaceuticals Inc Sub Pfizer Inc
Ingredients: Tafamidis Meglumine
Treatment: Transthyretin Amyloid Polyneuropathy

Lynparza
Olaparib

Sales:
$259 Million (Jan-Sep 2019)

PatentsExpiration Date
US7151102April 29, 2022
US7449464October 11, 2024
US7981889October 11, 2024
US8912187March 12, 2024

Dosage: Capsule; Oral
Company: AstraZeneca Pharmaceuticals LP
Ingredients: Olaparib
Treatment: Advanced Ovarian Cancer, Fallopian Tube Cancer

Tasigna
Nilotinib

Sales:
$1.88 Billion (2019)

PatentsExpiration Date
US7169791January 04, 2024
US8415363January 18, 2027
US8163904February 23, 2029
US9061029October 7, 2032

Dosage: Capsule; Oral
Company: Novartis Pharmaceuticals Corp
Ingredients: Nilotinib Hydrochloride
Treatment: Chronic Myelogenous Leukemia

Xopenex HFA
Levalbuterol Tartrate

Sales:
$148 Million (2012)

PatentsExpiration Date
US7256310October 08, 2024

Dosage: Aerosol, Metered; Inhalation
Company: Sunovion Pharmaceuticals Inc
Ingredients: Levalbuterol Tartrate
Treatment: Asthma and Chronic Obstructive Pulmonary Disease (COPD)

Vandazole
Metronidazole

Sales:
–

PatentsExpiration Date
US7456207September 22, 2024

Dosage: Gel; Vaginal
Company: Teva Pharmaceuticals USA
Ingredients: Metronidazole
Treatment: Bacterial Vaginosis

Prialt
Ziconotide Acetate

Sales:
$27 Million (2017)

PatentsExpiration Date
US8653033October 10, 2024
US8765680October 10, 2024
US9707270October 10, 2024

Dosage: Injectable; Intrathecal
Company: TerSera Therapeutics LLC
Ingredients: Ziconotide Acetate
Treatment: Pain Reliever

Aloxi
Palonosetron Hydrochloride

Sales:
$400 Million (2019)

PatentsExpiration Date
US7947724January 30, 2024
US7947725January 30, 2024
US7960424January 30, 2024
US8518981January 30, 2024
US8598218January 30, 2024
US9173942January 30, 2024
US9439854January 30, 2024
US9457020January 30, 2024

Dosage: Injectable; Intravenous
Company: Helsinn Healthcare SA
Ingredients: Palonosetron Hydrochloride
Treatment: Acute Nausea and Vomiting

Dificid
Fidaxomicin

Sales:
$60 Million (2021)

PatentsExpiration Date
US8586551January 23, 2024
US7378508January 31, 2028
US7863249January 31, 2028

Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: FIDAXOMICIN
Treatment: Clostridioides difficile-associated Diarrhea (CDAD)

Linzess
Linaclotide

Sales:
$287 Million (2021)

PatentsExpiration Date
US7371727January 28, 2024
US7745409January 28, 2024
US8080526January 28, 2024
US7704947January 28, 2024
US7304036August 30, 2026

Dosage: Oral
Company: Allergan
Ingredients: LINACLOTIDE
Treatment: Irritable Bowel Syndrome

Myfembree
Relugolix/estradiol/norethisterone acetate

Sales:
–

PatentsExpiration Date
US7300935January 28, 2024
US8058280January 28, 2024

Dosage: Oral
Company: Myovant Sciences
Ingredients: ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX
Treatment: Heavy Menstrual Bleeding

Ferric Citrate
Ferric Citrate

Sales:
–

PatentsExpiration Date
US9328133February 18, 2024
US9757416February 18, 2024
US8338642February 18, 2024
US7767851February 18, 2024

Dosage: Oral
Company: Akebia Therapeutics
Ingredients: FERRIC CITRATE
Treatment: Hyperphosphataemia and Iron Deficiency Anaemia

Ofev/Vargatef
Nintedanib

Sales:
–

PatentsExpiration Date
US7119093February 21, 2024
US6762180October 1, 2025

Dosage: Oral
Company: Boehringer Ingelheim
Ingredients: NINTEDANIB ESYLATE
Treatment: Idiopathic Pulmonary Fibrosis

Isentress
Raltegravir

Sales:
–

PatentsExpiration Date
US7119093February 21, 2024
US6762180October 1, 2025

Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: RALTEGRAVIR POTASSIUM
Treatment: HIV/AIDS

Zontivity
Vorapaxar

Sales:
–

PatentsExpiration Date
US7304078April 6, 2024
US7713999May 30, 2024

Dosage: Oral
Company: Merck Sharp & Dohme Corp
Ingredients: VORAPAXAR SULFATE
Treatment: Peripheral Arterial Disease

Bosulif
Bosutinib

Sales:
$23 Million (2020)

PatentsExpiration Date
USRE42376April 13, 2024
US7767678November 23, 2026

Dosage: Oral
Company: Pfizer
Ingredients: BOSUTINIB MONOHYDRATE
Treatment: Chronic Myelogenous Leukemia

Omontys
Peginesatide

Sales:
–

PatentsExpiration Date
US7084245May 12, 2024
US7414105May 12, 2024
US7919118May 12, 2024
US7528104May 12, 2024

Dosage: Subcutaneous, intravenous
Company: Affymax Inc.
Ingredients: PEGINESATIDE ACETATE
Treatment: Anemia

Aliqopa
Copanlisib

Sales:
–

PatentsExpiration Date
US7511041May 13, 2024
USRE46856October 22, 2029
US10383876March 29, 2032

Dosage: Intravenous infusion
Company: Bayer
Ingredients: COPANLISIB DIHYDROCHLORIDE
Treatment: Relapsed follicular lymphoma

Mayzent
Siponimod

Sales:
–

PatentsExpiration Date
US7939519May 19, 2024

Dosage: Oral
Company: Novartis
Ingredients: SIPONIMOD FUMARIC ACID
Treatment: Multiple Sclerosis

Prevymis
Letermovir

Sales:
$281 Million (2020)

PatentsExpiration Date
US8513255May 22, 2024
USRE46791May 22, 2024

Dosage: Oral, Intravenous
Company: Merck & Co
Ingredients: LETERMOVIR
Treatment: Cytomegalovirus

Xifaxan
Rifaximin

Sales:
–

PatentsExpiration Date
US7612199June 19, 2024
US8835452June 19, 2024
US8158781June 19, 2024
US7045620June 19, 2024
US7902206June 19, 2024
US7906542June 1, 2025
US8741904February 27, 2026
US8193196September 2, 2027

Dosage: Oral
Company: Salix Pharmaceuticals
Ingredients: RIFAXIMIN
Treatment: Travelers’ Diarrhea, Irritable Bowel Syndrome

Remodulin/Orenitram/Tyvaso
Treprostinil

Sales:
–

PatentsExpiration Date
US9050311May 24, 2024
US7417070July 30, 2026
US8497393December 15, 2028

Dosage: Subcutaneous, intravenous, inhalation, Oral
Company: United Therapeutics
Ingredients: TREPROSTINIL DIOLAMINE
Treatment: Pulmonary arterial hypertension

Tpoxx
Tecovirimat

Sales:
–

PatentsExpiration Date
US8124643June 18, 2024
US9339466March 23, 2031

Dosage: Oral
Company: SIGA Technologies
Ingredients: TECOVIRIMAT
Treatment: Orthopoxviruses (Smallpox and Monkeypox)

Nuvigil
Armodafinil

Sales:
–

PatentsExpiration Date
US7132570June 18, 2024

Dosage: Oral
Company: Teva Pharmaceuticals
Ingredients: ARMODAFINIL
Treatment: Excessive Daytime Sleepiness

Oriahnn
Elagolix/estradiol/norethindrone acetate

Sales:
$145 Million (2021)

PatentsExpiration Date
US7419983July 6, 2024
US7056927September 10, 2024

Dosage: Oral
Company: AbbVie Inc.
Ingredients: ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE
Treatment: Heavy Menstrual Bleeding

Xeglyze
Abametapir

Sales:
–

PatentsExpiration Date
US9839631July 16, 2024

Dosage: Topical
Company: Dr. Reddy’s Laboratories
Ingredients: ABAMETAPIR
Treatment: Head Lice Infestation

Ninlaro
Ixazomib

Sales:
–

PatentsExpiration Date
US8546608August 12, 2024
US8003819August 6, 2027
US8530694August 6, 2027
US7687662August 6, 2027
US8859504June 16, 2029
US7442830November 20, 2029

Dosage: Oral
Company: Takeda
Ingredients: IXAZOMIB CITRATE
Treatment: Multiple Myeloma

Prezista
Darunavir

Sales:
–

PatentsExpiration Date
US8518987August 16, 2024
US7700645June 26, 2027

Dosage: Oral
Company: Janssen Therapeutics
Ingredients: DARUNAVIR
Treatment: HIV/AIDS

Xarelto
Rivaroxaban

Sales:
–

PatentsExpiration Date
US7157456August 28, 2024

Dosage: Oral
Company: Janssen Therapeutics
Ingredients: RIVAROXABAN
Treatment: Blood clots

MoviPrep
POLYETHYLENE GLYCOL 3350

Sales:
–

PatentsExpiration Date
US7169381September 1, 2024
US7658914September 1, 2024

Dosage: Oral
Company: Velinor A.G
Ingredients: ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE
Treatment: Use for Colonoscopy Bowel Preparation

Aldara
Imiquimod

Sales:
–

PatentsExpiration Date
US7696159October 1, 2024

Dosage: Topical
Company: 3M Pharmaceutical
Ingredients: IMIQUIMOD
Treatment: Genital Warts, Superficial Basal cell carcinoma, and Actinic Keratosis

Brilinta
Ticagrelor

Sales:
$1.4 Billion (2021)

PatentsExpiration Date
USRE46276October 30, 2024

Dosage: Oral
Company: AstraZeneca
Ingredients: TICAGRELOR
Treatment: Stroke, Heart Attack

Xiidra
Lifitegrast

Sales:
$1.4 Billion (2021)

PatentsExpiration Date
US7745460November 5, 2024
US7928122November 5, 2024
US7314938March 10, 2025
US8084047May 17, 2026
US9890141October 21, 2030

Dosage: Eye Drops
Company: Novartis
Ingredients: LIFITEGRAST
Treatment: Signs and Symptoms of Dry Eye

Nourianz
Istradefylline

Sales:
–

PatentsExpiration Date
US7541363November 13, 2024

Dosage: Oral
Company: Kyowa Kirin Co.
Ingredients: ISTRADEFYLLINE
Treatment: Levodopa/Carbidopa in adults with Parkinson’s disease

Ponvory
Ponesimod

Sales:
–

PatentsExpiration Date
USRE43728November 16, 2024
US9062014May 6, 2032

Dosage: Oral
Company: Janssen Pharmaceuticals
Ingredients: PONESIMOD
Treatment: Multiple Sclerosis

Tukysa
Tucatinib

Sales:
–

PatentsExpiration Date
US7452895November 16, 2024
US8648087April 12, 2031

Dosage: Oral
Company: Seagen Inc
Ingredients: TUCATINIB
Treatment: HER2-positive Breast Cancer

Asclera/Aethoxysklerol/Varithena
Polidocanol

Sales:
–

PatentsExpiration Date
US7731986November 17, 2024

Dosage: Topical, Subcutaneous Injection
Company: Methapharm, Inc.
Ingredients: POLIDOCANOL
Treatment: Itching caused by Eczema and Dry Skin

Zepzelca
Lurbinectedin

Sales:
–

PatentsExpiration Date
US7763615December 13, 2024

Dosage: Intravenous Injection
Company: PharmaMar, S.A.
Ingredients: LURBINECTEDIN
Treatment: Metastatic Small Cell Lung Cancer (SCLC)

Victrelis
Boceprevir

Sales:
–

PatentsExpiration Date
USRE43298December 22, 2024

Dosage: Oral
Company: Merck & Co
Ingredients: BOCEPREVIR
Treatment: Hepatitis caused by Hepatitis C virus (HCV) genotype 1

Comments

Leave a Comment

Become a part of GreyB’s insider list

Get our distilled learning delivered to you.

Get the Sample Report

Fill out the form and get the report.